Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

face elderly woman forehead wrinkles before and after cosmetic procedures
Neurotoxins filled the forehead wrinkle niche, but unmet needs remain, including undereye bags. • Source: Shutterstock

Every big success in the biopharmaceutical industry ends up with competitors looking to develop their own versions of a blockbuster drug, and the medical aesthetics arena is no different with multiple challengers approved or on the way for Allergan PLC's Botox (onabotulinumtoxinA).

Aesthetics Market Review

This article is the third in a series of three about the medical aesthetics market. Part 1 covered the key players in this area while the second part looked at DTC and other marketing strategies.

Botox generated $3.17bn in 2017 sales across its aesthetic and therapeutic indications, and with $1.75bn in sales during the first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.